Cipla Secures USFDA Nod For First Generic Ventolin HFA, Launch Planned In FY2026-27

Cipla Ltd, a leading global pharmaceutical company, has achieved a significant milestone with USFDA approval for its generic Ventolin HFA inhaler. This marks the first AB-rated generic of the widely prescribed asthma and COPD medication, positioning Cipla to enter a critical therapeutic segment in the United States.

Regulatory Approval

The USFDA clearance underscores Cipla’s compliance with stringent quality and safety standards. The AB-rating ensures therapeutic equivalence with the branded Ventolin HFA, offering patients a reliable and cost-effective alternative.

Market Significance

Ventolin HFA is one of the most prescribed rescue inhalers for asthma and COPD patients. Cipla’s entry into this segment is expected to enhance competition, reduce treatment costs, and strengthen its presence in the US respiratory market.

Strategic Outlook

The launch in H1 FY2026-27 aligns with Cipla’s strategy to expand its generics portfolio in regulated markets. This move reinforces its commitment to delivering affordable healthcare solutions globally while boosting revenue growth from the US market.

Key Highlights

• Cipla receives USFDA approval for generic Ventolin HFA
• First AB-rated generic of albuterol sulfate inhalation aerosol
• Launch planned in H1 FY2026-27 in US market
• Strengthens Cipla’s respiratory portfolio and generics presence
• Supports affordable treatment options for asthma and COPD patients

Sources: Company Announcements, Business Standard, Economic Times, Mint